Halozyme Therapeutics, Inc. announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari was Group Head, Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In addition, he was Chairman of Celgene's hematology oncology development committee and a member of the company's management committee.

Dr. Bizzari is a member of the Scientific Advisory Board of France'sNational Cancer Institute and is a board member of Transgene.